The countdown to ESC Congress 2019 is nearing its end. The world's premier Cardiovascular congress is now just less than 4 weeks away! The program spans from Saturday Aug 31 to Wednesday Sept 4.
Among the late-breaking science session, Prof. Müller will present the data of the GALACTIC trial (“Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial”) at 11:36 on Monday in the main auditorium.
Also the main results of THEMIS (“Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study”) and ISAR-REACT 5 (“Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome”) will be presented and discussed.
The ESC TV services will broadcast throughout the congress. As an example, the PARAGON-HF (“Angiotensin Receptor Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction”) t will be discussed on TV by Scott Solomon on Sunday at 16:25. Stay tuned in the right channel.
To be mentioned also that the data of AFIRE (“Rivaroxaban monotherapy versus combination therapy in patients with atrial fibrillation and stable coronary artery disease”) will be disclosed.
As it regards the LEODOR study (“repetitive use of levosimendan in advanced heart failure patients”), an investigator meeting will be held to discuss about the progress in initiation of the centers and enrollment of the patients. The study protocol will be discussed in a satellite symposium in “The HUB Duras” on Monday Sept 2 from 13:00 to 13:45
The chairpersons of the symposium will be John T PARISSIS (Athens, Greece) and Francesco FEDELE (Roma, Italy), while the lectures and discussions will be held by Finn GUSTAFSSON (Copenhagen, Denmark), Veli-Pekka HARJOLA (Helsinki, Finland), yours truly Gerhard POLZL (Innsbruck, Austria), Josep COMIN-COLET (Hospitalet De Llobregat, Spain), Piergiuseppe AGOSTONI (Milan, Italy), and Carsten TSCHOEPE (Berlin, Germany).
The use of inotropes for correcting hemodynamic dysfunction and relieving symptoms in patients with congestive heart failure will be debated. Unfortunately, negative or insufficient data has been collected on the effects of cardiac glycosides, cathecolamines and phosphodiesthrase inhibitors on quality of life and survival. However, drugs which are both calcium sensitizers and potassium channels openers – such as levosimendan - have been proposed as safer inodilators in acute and advanced heart failure.